Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2013-01-29 Annual Report
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
FORM 10-K
Annual Report FY 2012
2013-01-29 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions the completion of an offering of convertible debentures and warrants, which is a financing activity. It also references that additional information will be in the Annual Report (10-K), indicating this document is an update rather than a full financial report. The document length is short (2791 characters), and it includes a press release as an exhibit. The content focuses on a capital raising event, not on financial results or management changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2013-01-28 English
PRIMARY DOCUMENT
Director's Dealing
2012-12-07 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It includes disclosures about unregistered sales of equity securities, changes in the board of directors, and the submission of matters to a vote of security holders with detailed voting results. The presence of board appointments and voting results indicates it is not a full annual report or earnings release but rather a current report on significant corporate events. The detailed voting results from the Annual Meeting correspond to a Declaration of Voting Results. Therefore, the document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and content confirm it is not a mere announcement but a full report of voting results and management changes, supporting a high confidence score.
2012-12-04 English
PRIMARY DOCUMENT
Director's Dealing
2012-12-04 English
PRIMARY DOCUMENT
Director's Dealing
2012-12-04 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.